<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="114.00-Immune-Childhood">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>114.00 Immune System Disorders | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"true","rua.uprl":"false","rua.cprl":"true","rua.cprf":"false","rua.trans":"SJ-58bf15e4-70d6-4d49-bc49-6919f38410b4","rua.cook":"true","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"true","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n="true"=="true"?1:0,t="cookiepresent",a="im6jsaqx2s43i2inl3ca-f-7f91d0cd6-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":22,"ak.ipv":4,"ak.proto":"h3","ak.rid":"13d7e754","ak.r":49961,"ak.a2":n,"ak.m":"","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":62166,"ak.gh":"23.210.6.47","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762483908","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==t3Q3+2cQ27NzTHSrI3Q2Ijg4JAm9gS0Bk6r5nUajwelZSZldckDz9II5PaPe0jqlVDqo4ubwPygZ4kIpAFl2xWjWF3c+DM8eNcUIGxPzd8mEqUQ6hJxgRKYi76bLJctBrPCr6qTOl2RB/77MeYrOdCoukopHvjlzJf1b7oiAlq/vFk4c67eJqB6T65dG8dQ7m4NDeQG8Nne9mwimcLfSZ36rI1k2ybCfYeJ2r4JFpn+D1Nden9yfOnBNZnQ+/VYh/DsI+mpB/URr3trq9y/wfs/vX4Moql1skE1kO4+xS1f4j+H/gt+Qa35/4bIRTEW081zC6BsxfiQoMSGf7lp4QR56JZAD2GX4GIUTJiQTQUVgLPY9fzzVXeOB3ugVaAnD7Tf1kO/9UjMyuRyx70wy1aK5t0IDFCLEPzTNvrKlxcQ=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/114.00-Immune-Childhood.htm#114_00"><meta property="og:title" content="114.00 Immune System Disorders | Disability | SSA"><meta property="og:description" content="114.00-Immune-Childhood"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2>
        </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="ChildhoodListings.htm">Listing of Impairments - Child Listings (Part B)</a></li> 
    <li aria-current="page">114.00 Immune System Disorders - Childhood</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

         <h2><span><b> Disability Evaluation Under Social Security<br>
        <br>
        114.00 Immune System Disorders - Childhood<br>
        &nbsp;</b></span></h2>
        
                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>

	        <p align="left">  
                <a href="#114_01"><strong>114.01</strong><br>
              Category 
              of Impairments, Immune System Disorders</a><br><br>
              <a href="#114_02"><strong>114.02</strong><br>
              Systemic lupus erythematosus</a><br>
              <br>
              <a href="#114_03"><strong>114.03</strong><br>
              Systemic vasculitis</a><br>
              <br>
              <a href="#114_04"><strong>114.04</strong><br>
              Systemic sclerosis (scleroderma)</a><br>
              <br>
              <a href="#114_05"><strong>114.05</strong><br>
              Polymyositis or dermatomyositis</a><br>
              <br>
              <a href="#114_06"><strong>114.06</strong><br>
              Undifferentiated and mixed connective tissue disease</a><br>
              <br>
              <a href="#114_07"><strong>114.07</strong><br>
              Immune deficiency disorders, excluding HIV infection</a><br>
              <br>
              <a href="#114_08"><strong>114.08</strong><br>
              [Reserved]</a><br>
              <br>
              
              <a href="#114_09"><strong>114.09</strong><br>
              Inflammatory arthritis</a><br>
              <br>
               
              </p><p align="left"><a href="#114_10"><strong>114.10</strong><br>
            Sjögren’s syndrome</a><br>
              <br>
               
              </p><p align="left"><a href="#114_11"><strong>114.11</strong><br>
            Human immunodeficiency virus (HIV) infection</a>
            
                            </p></article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
  <p id="114_00"><u><b>114.00 Immune System Disorders </b></u></p>
   
      <p id="114_00A"><strong>A.</strong> <em>What disorders</em> <em>do we evaluate under the immune system </em><em>disorders listings?</em>
    </p>
    <p id="114_00A1">1. <em>We evaluate  immune system disorders that cause dysfunction in one or more components of  your immune system.</em>&nbsp; </p>
            <p id="114_00A1a">a. The dysfunction may be due to problems in antibody  production, impaired cell-mediated immunity, a combined type of  antibody/cellular deficiency, impaired phagocytosis, or complement deficiency. </p>
            <p id="114_00A1b">b. Immune system disorders may result in recurrent and  unusual infections, or inflammation and dysfunction of the body’s own tissues.  Immune system disorders can cause a deficit in a single organ or body system  that results in extreme (that is, very serious) loss of function. They can also  cause lesser degrees of limitations  in two or more organs or body systems, and when associated with symptoms or signs, such as severe  fatigue, fever, malaise, diffuse  musculoskeletal pain, or involuntary weight loss, can also result in extreme limitation. In children, immune system disorders or their  treatment may also affect growth, development, and the performance of age‑appropriate  activities. </p>
            <p id="114_00A1c">c. We organize the discussions of immune system  disorders in three categories: Autoimmune disorders; Immune deficiency  disorders, excluding human immunodeficiency virus (HIV) infection; and HIV  infection.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00A2">
                2. <em>Autoimmune disorders (<a href="#114_00D" title="Section 114.00 - Subsection D">114.00D</a>). </em>
                Autoimmune disorders are caused by dysfunctional immune responses directed against the body’s own tissues, resulting in chronic,
                multisystem impairments that differ in clinical manifestations, course, and outcome.
                They are sometimes referred to as rheumatic diseases, connective tissue disorders, or collagen vascular disorders.
                Some of the features of autoimmune disorders in children differ from the features of the same disorders in adults.
                The impact of the disorders or their treatment on physical, psychological, and developmental growth of  pre-pubertal children may be considerable,
                and often differs from that of post-pubertal adolescents or adults.
            </p>
            <p id="114_00A3">
                3. <em>Immune deficiency disorders, excluding HIV infection (<a href="#114_00E" title="Section 114.00 - Subsection E">114.00E</a>). </em>
                Immune deficiency disorders are characterized by recurrent or unusual infections that respond poorly to treatment, and are often  associated with complications affecting other parts of the body.
                Immune deficiency disorders are classified as either <em>primary</em> (congenital) or <em>acquired</em>.
                Children with immune deficiency disorders also have an increased risk of malignancies and of having autoimmune disorders.
            </p>
            <p id="114_00A4">
                4.<em> Human immunodeficiency virus (HIV) infection (<a href="#114_00F" title="Section 114.00 - Subsection F">114.00F</a>).</em>
                HIV infection may be characterized by increased susceptibility to common infections as well as opportunistic infections, cancers,
                or other conditions listed in <a href="#114_11" title="Section 114.11">114.11</a>.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00B"><strong>B. </strong><em>What information do we need to show that you have an immune system  disorder?</em> Generally, we need your medical  history, a report(s) of a physical examination, a report(s) of laboratory  findings, and in some instances, appropriate medically acceptable imaging or  tissue biopsy reports to show that you have an immune system disorder.  Therefore, we will make every reasonable effort to obtain your medical history, medical findings, and results of laboratory tests. We explain the information we need  in more detail in the sections below. </p>
            <p id="114_00C"><strong>C. </strong><em>Definitions</em> </p>
            <p id="114_00C1">1. <em>Appropriate medically acceptable imaging</em> includes, but is not limited to, angiography, x-ray imaging, computerized axial tomography (CAT scan) or magnetic resonance imaging (MRI), with or without contrast material,  myelography, and radionuclear bone scans. “Appropriate” means that the  technique used is the proper one to support the evaluation and diagnosis of the  impairment.</p>
            <p id="114_00C2">2. <em>Constitutional symptoms or signs</em>, as used in these listings, means  severe fatigue, fever, malaise, or involuntary weight loss. <em>Severe fatigue</em> means a frequent sense of exhaustion that results in significantly reduced  physical activity or mental function. <em>Malaise</em> means frequent feelings of  illness, bodily discomfort, or lack of well-being that result in significantly  reduced physical activity or mental function.&nbsp;&nbsp;&nbsp; </p>
            <p id="114_00C3">3. <em>Disseminated</em> means that a condition  is spread over a considerable area. The type and extent of the spread will  depend on your specific disease.</p>
            <p id="114_00C4">4. <em>Dysfunction</em> means that one or more of the body regulatory mechanisms are impaired, causing  either an excess or deficiency of immunocompetent cells or their products.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00C5">5. <em>Extra-articular</em> means “other than the joints”; for example, an organ(s) such as the heart,  lungs, kidneys, or skin.</p>
            <p id="114_00C6">
                6. <em>Documented medical need </em>
                 has the same meaning as in <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6a" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6a" target="_blank">101.00C6a</a>.
            </p>
            <p id="114_00C7">
                7. <em>Fine and gross movements </em>
                has the same meaning as in <a href="101.00-Musculoskeletal-Childhood.htm#101_00E4" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection E4" target="_blank">101.00E4</a>.
            </p>
            <p id="114_00C8">
                8. <em>Major joint of an upper or a lower extremity </em>
                has the same meaning as in <a href="101.00-Musculoskeletal-Childhood.htm#101_00I2" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection I2" target="_blank">101.00I2</a> and <a href="101.00-Musculoskeletal-Childhood.htm#101_00I3" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection I3" target="_blank">101.00I3</a>.
            </p>
            <p id="114_00C9">9. <em>Persistent</em> means that a sign(s) or symptom(s) has continued over  time. The precise meaning will depend on the specific immune system disorder,  the usual course of the disorder, and the other circumstances of your clinical  course.</p>
            <p id="114_00C10">10. <em>Recurrent</em> means that a condition that previously responded  adequately to an appropriate course of treatment returns after a period of  remission or regression. The precise meaning, such as the extent of response or  remission and the time periods involved, will depend on the specific disease or  condition you have, the body system affected, the usual course of the disorder  and its treatment, and the other facts of your particular case.</p>
            <p id="114_00C11">11. <em>Resistant to treatment</em> means that a  condition did not respond adequately to an appropriate course of treatment.  Whether a response is adequate or a course of treatment is appropriate will  depend on the specific disease or condition you have, the body system affected,  the usual course of the disorder and its treatment, and the other facts of your  particular case.&nbsp; </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00C12">
                12. <em>Severe </em>means medical severity as used by the medical community.
                The term does not have the same meaning as it does when we use it in connection with a finding at the second step of the sequential evaluation process
                in § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm" target="_blank" title="Code of Federal Regulations section 416.924">416.920</a> of this chapter.
            </p>
            <p id="114_00D"><strong>D. </strong><em>How do we document and evaluate the listed autoimmune disorders?<strong> </strong></em></p>
            <p id="114_00D1">1. <em>Systemic lupus erythematosus (<a href="#114_02" title="Section 114.02">114.02</a>).</em> </p>
            <p id="114_00D1a">a. <em>General. </em>Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that can affect any organ or body  system. It is frequently, but not always, accompanied by constitutional  symptoms or signs (severe fatigue, fever, malaise, involuntary weight loss).  Major organ or body system involvement can include: Respiratory (pleuritis,  pneumonitis), cardiovascular (endocarditis, myocarditis, pericarditis,  vasculitis), renal (glomerulonephritis), hematologic (anemia, leukopenia,  thrombocytopenia), skin (photosensitivity), neurologic (seizures), mental  (anxiety, fluctuating cognition (“lupus fog”), mood disorders, organic brain  syndrome, psychosis), or immune system disorders (inflammatory arthritis).  Immunologically, there is an array of circulating serum auto-antibodies and  pro- and anti-coagulant proteins that may occur in a highly variable pattern. </p>
            <p id="114_00D1b">b. <em>Documentation of SLE. </em>Generally, but not always, the medical evidence will show that your SLE satisfies the criteria in the current “Criteria for the Classification of Systemic Lupus  Erythematosus” by the American College of Rheumatology found in the most recent  edition of the <em>Primer on the Rheumatic Diseases</em> published by the  Arthritis Foundation.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D2">2. <em>Systemic vasculitis (<a href="#114_03" title="Section 114.03">114.03</a>).</em> </p>
            <p id="114_00D2a">a. <em>General.</em> </p>
            <p id="114_00D2ai">(i) Vasculitis is an inflammation of blood vessels. It may occur acutely in  association with adverse drug reactions, certain chronic infections, and  occasionally, malignancies. More often, it is chronic and the cause is unknown.  Symptoms vary depending on which blood vessels are involved. Systemic  vasculitis may also be associated with other autoimmune disorders; for example,  SLE or dermatomyositis. </p>
            <p id="114_00D2aii">
                (ii) Children can develop the vasculitis of Kawasaki disease,
                of which the most serious manifestation is formation of coronary artery aneurysms and related complications.
                We evaluate heart problems related to Kawasaki disease under the criteria in the cardiovascular listings 
                (<a href="104.00-Cardiovascular-Childhood.htm#104_00" target="_blank" title="104.00 Cardiovascular System - Childhood Page, Section 104.00">104.00</a>).
                Children can also develop the vasculitis of anaphylactoid purpura (Henoch-Schoenlein purpura), which may cause intestinal and renal disorders.
                We evaluate intestinal and  renal disorders related to vasculitis of anaphylactoid purpura under the criteria in the digestive
                (<a href="105.00-Digestive-Childhood.htm#105_00" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.00">105.00</a>) or
                genitourinary (<a href="106.00-Genitourinary-Childhood.htm#106_00" target="_blank" title="106.00 Genitourinary Disorders - Childhood Page, Section 106.00">106.00</a>) listings.
                Other clinical patterns include, but are not limited to, polyarteritis nodosa,
                Takayasu’s arteritis (aortic arch arteritis), and Wegener’s granulomatosis.
            </p>
            <p id="114_00D2b">b. <em>Documentation of systemic vasculitis. </em>Angiography or tissue biopsy confirms a diagnosis of systemic vasculitis when the disease is suspected clinically. When you have had angiography or tissue biopsy for  systemic vasculitis, we will make every reasonable effort to obtain reports of  the results of that procedure. However, we will not purchase angiography or  tissue biopsy.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D3">3. <em>Systemic sclerosis (scleroderma) (<a href="#114_04" title="Section 114.04">114.04</a>). </em></p>
            <p id="114_00D3a">a. <em>General. </em>Systemic sclerosis  (scleroderma) constitutes a spectrum of disease in which thickening of the skin  is the clinical hallmark. Raynaud’s phenomenon, often medically severe and  progressive, is present frequently and may be the peripheral manifestation of a  vasospastic abnormality in the heart, lungs, and kidneys. The CREST syndrome  (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, and  telangiectasia) is a variant that may slowly progress over years to the  generalized process, systemic sclerosis. </p>
            <p id="114_00D3b">b. <em>Diffuse cutaneous systemic sclerosis. </em>In  diffuse cutaneous systemic sclerosis (also known as diffuse scleroderma), major  organ or systemic involvement can include the gastrointestinal tract, lungs,  heart, kidneys, and muscle in addition to skin or blood vessels. Although  arthritis can occur, joint dysfunction results primarily from soft  tissue/cutaneous thickening, fibrosis, and contractures. </p>
            <p id="114_00D3c">c. <em>Localized scleroderma (linear scleroderma  and morphea).</em> </p>
            <p id="114_00D3ci">
                (i) Localized scleroderma (linear scleroderma and  morphea) is more common in children than systemic scleroderma.
                To assess the severity of the impairment, we need a description of the extent of involvement of linear scleroderma and the location of the lesions.
                For example, linear scleroderma involving the arm but not crossing any joints is not as functionally limiting as sclerodactyly (scleroderma localized to the fingers).
                Linear scleroderma of a lower extremity involving skin thickening and atrophy of underlying muscle or bone can result in contractures and leg length discrepancy.
                In such cases, we may evaluate your impairment under the musculoskeletal listings 
                (<a href="101.00-Musculoskeletal-Childhood.htm#101_00" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00" target="_blank">101.00</a>).
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D3cii"> 
                (ii) When there is isolated morphea of the face causing facial disfigurement from unilateral hypoplasia of the mandible,
                maxilla, zygoma, or orbit, adjudication  may be more appropriate under the criteria in the affected body system,
                such as special senses and speech (<a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>)
                or mental disorders (<a href="112.00-MentalDisorders-Childhood.htm#112_00" target="_blank" title="112.00 Mental Disorders - Childhood Page, Section 112.00">112.00</a>).&nbsp;
            </p>
            <p id="114_00D3ciii">
                (iii) Chronic variants of these syndromes include disseminated morphea, Shulman’s  disease (diffuse fasciitis with eosinophilia),
                and eosinophilia-myalgia syndrome (often associated with toxins such as toxic oil or contaminated tryptophan),
                all of which can impose medically severe musculoskeletal dysfunction and may also lead to restrictive pulmonary disease.
                We evaluate these variants of the disease under the criteria in the musculoskeletal listings
                (<a href="101.00-Musculoskeletal-Childhood.htm#101_00" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00" target="_blank">101.00</a>) or
                respiratory system listings (<a href="103.00-Respiratory-Childhood.htm#103_00" target="_blank" title="103.00 Respiratory Disorders - Childhood Page, Section 103.00">103.00</a>).
            </p>
            <p id="114_00D3d">d. <em>Documentation of systemic sclerosis (scleroderma). </em>Documentation involves differentiating the clinical features  of systemic sclerosis (scleroderma) from other autoimmune disorders. However,  there may be an overlap<em>.</em> </p>
            <p id="114_00D4">4. <em>Polymyositis and dermatomyositis (<a href="#114_05" title="Section 114.05">114.05</a>).</em><u> </u></p>
            <p id="114_00D4a">a. <em>General.</em> </p>
            <p id="114_00D4ai">(i) Polymyositis and dermatomyositis are related  disorders that are characterized by an inflammatory process in striated muscle,  occurring alone or in association with other autoimmune disorders. The most  common manifestations are symmetric weakness, and less frequently, pain and  tenderness of the proximal limb-girdle (shoulder or pelvic) musculature. There  may also be involvement of the cervical, cricopharyngeal, esophageal,  intercostal, and diaphragmatic muscles. </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D4aii">(ii) Polymyositis occurs rarely in children; the more  common presentation in children is dermatomyositis with symmetric proximal muscle weakness and characteristic skin findings. The clinical course of  dermatomyositis can be more severe when it is accompanied by systemic  vasculitis rather than just localized to striated muscle. Late in the disease,  some children with dermatomyositis develop calcinosis of the skin and  subcutaneous tissues, muscles, and joints. We evaluate the involvement of other  organs/body systems under the criteria for the listings in the affected body  system.</p>
            <p id="114_00D4b">b. <em>Documentation  of polymyositis and dermatomyositis. </em>Generally, but not always,  polymyositis is associated with elevated serum muscle enzymes (creatine  phosphokinase (CPK), aminotransferases, and aldolase), and characteristic  abnormalities on electromyography and muscle biopsy. In children, the diagnosis  of dermatomyositis is supported largely by medical history, findings on  physical examination that include the characteristic skin findings, and  elevated serum muscle enzymes. Muscle inflammation or vasculitis depicted on  MRI is additional evidence supporting the diagnosis of childhood  dermatomyositis. When you have had electromyography, muscle biopsy, or MRI for  polymyositis or dermatomyositis, we will make every reasonable effort to obtain  reports of the results of that procedure. However, we will not purchase  electromyography, muscle biopsy, or MRI.&nbsp; </p>
            <p id="114_00D4c">c. <em>Additional information about how we  evaluate polymyositis and dermatomyositis under the listings.</em> </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D4ci">
                (i) In newborn and younger infants (birth  to attainment of age 1), we consider muscle weakness that affects motor skills, such as head control,
                reaching, grasping, taking solids, or self-feeding, under <a href="#114_05A" title="Section 114.05 - Subsection A">114.05A</a>.
                In older infants and toddlers (age 1 to attainment of age 3), we also consider muscle weakness affecting your ability to roll over, sit, crawl,
                or walk under <a href="#114_05A" title="Section 114.05 - Subsection A">114.05A</a>.
            </p>
            <p id="114_00D4cii">
                (ii) If you are of preschool age through  adolescence (age 3 to attainment of age 18),
                weakness of your pelvic girdle muscles that results in your inability to rise independently from a squatting
                or sitting position or to climb stairs may be an indication that you are unable to walk without assistance.
                Weakness of your shoulder girdle muscles may result in  your inability to perform lifting, carrying, and reaching overhead,
                and also may seriously affect your ability to perform activities requiring fine movements.
                We evaluate these limitations under <a href="#114_05A" title="Section 114.05 - Subsection A">114.05A</a>.
            </p>
            <p id="114_00D5">5. <em>Undifferentiated and mixed connective tissue disease (<a href="#114_06" title="Section 114.06">114.06</a>).</em> </p>
            <p id="114_00D5a">a. <em>General.</em> This listing includes syndromes with clinical and immunologic features of several autoimmune  disorders, but which do not satisfy the criteria for any of the specific  disorders described. For example, you may have clinical features of SLE and  systemic vasculitis, and the serologic (blood test) findings of rheumatoid  arthritis. The most common pattern of undifferentiated autoimmune disorders in  children is mixed connective tissue disease (MCTD).</p>
            <p id="114_00D5b">b. <em>Documentation of undifferentiated and  mixed connective tissue disease. </em>Undifferentiated connective tissue disease  is diagnosed when clinical features and serologic (blood test) findings, such  as rheumatoid factor or antinuclear antibody (consistent with an autoimmune  disorder) are present but do not satisfy the criteria for a specific disease.  Children with MCTD have laboratory findings of extremely high antibody titers  to extractable nuclear antigen (ENA) or ribonucleoprotein (RNP) without high  titers of anti-dsDNA or anti-SM antibodies. There are often clinical findings  suggestive of SLE or childhood dermatomyositis. Many children later develop  features of scleroderma. </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D6">6. <em>Inflammatory arthritis (<a href="#114_09" title="Section 114.09">114.09</a>).</em> </p>
            <p id="114_00D6a">
                a. <em>General. </em>The spectrum of inflammatory arthritis includes a vast array of disorders that differ in cause, course, and outcome.
                Clinically, inflammation of major joints in an upper or a lower extremity may be the dominant manifestation causing difficulties with walking or fine and gross movements;
                there may be joint pain, swelling, and tenderness. The arthritis may affect other joints, or cause less limitation in walking or fine and gross movements.
                However, in combination with extra-articular features, including constitutional symptoms or signs
                (severe fatigue, fever, malaise and involuntary weight loss),
                inflammatory arthritis may result in an extreme limitation.
                
            </p>
            <p id="114_00D6b">b. <em>Inflammatory arthritis involving the axial spine (spondyloarthropathy). </em>In children, inflammatory arthritis involving the axial spine may be associated with disorders such as:</p>
            <p id="114_00D6bi">(i)  Reactive arthropathies;</p>
            <p id="114_00D6bii">(ii)  Juvenile ankylosing spondylitis;</p>
            <p id="114_00D6biii">(iii)  Psoriatic arthritis;</p>
            <p id="114_00D6biv">(iv)  SEA syndrome (seronegative enthesopathy arthropathy syndrome); </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D6bv">(v)  Behçet’s disease; and</p>
            <p id="114_00D6bvi">(vi)  Inflammatory bowel disease.</p>
            <p id="114_00D6c">c. <em>Inflammatory  arthritis involving the peripheral joints. </em>In children, inflammatory arthritis involving peripheral joints may be associated with disorders such as:</p>
            <p id="114_00D6ci">(i)  Juvenile rheumatoid arthritis;</p>
            <p id="114_00D6cii">(ii)  Sjögren’s syndrome;</p>
            <p id="114_00D6ciii">(iii)  Psoriatic arthritis;</p>
            <p id="114_00D6civ">(iv)  Crystal deposition disorders (gout and pseudogout); </p>
            <p id="114_00D6cv">(v)  Lyme disease; and</p>
            <p id="114_00D6cvi">(vi)  Inflammatory bowel disease.</p>
            <p id="114_00D6d">d. <em>Documentation of inflammatory arthritis. </em>Generally, but not always, the diagnosis of inflammatory arthritis is based on the clinical features and serologic findings described in the most recent edition  of the <em>Primer on the Rheumatic Diseases</em> published by the Arthritis  Foundation. </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D6e">e. <em>How we evaluate inflammatory arthritis under the listings.</em> </p>
            <p id="114_00D6ei">
                (i) Listing-level severity in <a href="#114_09A" title="Section 114.09 - Subsection A">114.09A</a>
                and <a href="#114_09C1" title="Section 114.09 - Subsection C1">114.09C1</a> is shown by the presence of an impairment-related physical limitation of functioning.
                In <a href="#114_09C1" title="Section 114.09 - Subsection C1">114.09C1</a>,
                if you have the required ankylosis (fixation) of your cervical or dorsolumbar spine,
                we will find that you have a listing-level impairment-related physical limitation in your ability to see in front of you, above you, and to the side
                <!--Therefore, inability to ambulate effectively is implicit in
                <a href="#114_09C1" title="Section 114.09 - Subsection C1">114.09C1</a>-->, even though you might not require bilateral upper limb assistance.
            </p>
            <p id="114_00D6eii">
                (ii) Listing-level severity in <a href="#114_09B" title="Section 114.09 - Subsection B">114.09B</a> and 
                <a href="#114_09C2" title="Section 114.09 - Subsection C2">114.09C2</a> is shown
                by inflammatory arthritis that involves various combinations of complications (such as inflammation or deformity, extra-articular features, repeated manifestations, and constitutional symptoms and signs) of one or more major of one or more major joints in an upper or a lower extremity (see <a href="#114_00C8" title="Section 114.00 - Subsection C8">114.00C8</a>) or other joints.
                Extra-articular impairments may also meet listings in other body systems.
            </p>
            <p id="114_00D6eiii">(iii) Extra-articular features of inflammatory arthritis may involve any body system; for example: Musculoskeletal (heel enthesopathy), ophthalmologic (iridocyclitis,  keratoconjunctivitis sicca, uveitis), pulmonary (pleuritis, pulmonary fibrosis  or nodules, restrictive lung disease), cardiovascular (aortic valve  insufficiency, arrhythmias, coronary arteritis, myocarditis, pericarditis,  Raynaud’s phenomenon, systemic vasculitis), renal (amyloidosis of the kidney),  hematologic (chronic anemia, thrombocytopenia), neurologic (peripheral  neuropathy, radiculopathy, spinal cord or cauda equina compression with sensory  and motor loss), mental (cognitive dysfunction, poor memory), and immune system  (Felty’s syndrome (hypersplenism with compromised immune competence)).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00D6eiv">(iv) If both inflammation and chronic deformities are present, we evaluate your  impairment under the criteria of any appropriate listing. </p>
            <p id="114_00D7">7. <em>Sjögren’s syndrome (<a href="#114_10" title="Section 114.10">114.10</a>).</em></p>
            <p id="114_00D7a">a. <em>General.</em> </p>
            <p id="114_00D7ai">(i) Sjögren’s syndrome is an immune-mediated disorder of the exocrine glands.  Involvement of the lacrimal and salivary glands is the hallmark feature,  resulting in symptoms of dry eyes and dry mouth, and possible complications,  such as corneal damage, blepharitis (eyelid inflammation), dysphagia  (difficulty in swallowing), dental caries, and the inability to speak for  extended periods of time. Involvement of the exocrine glands of the upper  airways may result in persistent dry cough.</p>
            <p id="114_00D7aii">(ii) Many other organ systems may be involved, including musculoskeletal (arthritis, myositis), respiratory (interstitial fibrosis), gastrointestinal (dysmotility,  dysphagia, involuntary weight loss), genitourinary (interstitial cystitis,  renal tubular acidosis), skin (purpura, vasculitis,), neurologic (central  nervous system disorders, cranial and peripheral neuropathies), mental  (cognitive dysfunction, poor memory), and neoplastic (lymphoma). Severe fatigue  and malaise are frequently reported. Sjögren’s syndrome may be associated with  other autoimmune disorders (for example, rheumatoid arthritis or SLE); usually  the clinical features of the associated disorder predominate.</p>
            <p id="114_00D7b">b. <em>Documentation of Sjögren’s syndrome. </em>If you have Sjögren’s syndrome, the medical evidence will generally, but not  always, show that your disease satisfies the criteria in the current “Criteria  for the Classification of Sjögren’s Syndrome” by the American College  of Rheumatology found in the most recent edition of the <em>Primer on the  Rheumatic Diseases</em> published by the Arthritis Foundation.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00E"><strong>E. </strong><em>How do we document and evaluate immune deficiency disorders, excluding HIV infection</em><em>? </em></p>
            <p id="114_00E1">1. <em>General.</em> </p>
            <p id="114_00E1a">a. Immune deficiency disorders can be classified as:</p>
            <p id="114_00E1ai">(i) <em>Primary</em> (congenital); for example, X-linked agammaglobulinemia, thymic hypoplasia (DiGeorge syndrome), severe combined immunodeficiency (SCID), chronic  granulomatous disease (CGD), C1 esterase inhibitor deficiency.</p>
            <p id="114_00E1aii">(ii) <em>Acquired;</em>for example, medication-related.</p>
            <p id="114_00E1b">b. Primary immune deficiency disorders are seen mainly  in children. However, recent advances in the treatment of these disorders have  allowed many affected children to survive well into adulthood. Occasionally,  these disorders are first diagnosed in adolescence or adulthood.</p>
            <p id="114_00E2">2. <em>Documentation of immune deficiency disorders. </em>The medical evidence must include documentation of the specific  type of immune deficiency. Documentation may be by laboratory evidence or by  other generally acceptable methods consistent with the prevailing state of  medical knowledge and clinical practice. </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00E3">3. <em>Immune deficiency disorders treated by stem cell transplantation.</em> </p>
            <p id="114_00E3a">a. <em>Evaluation in the first 12 months. </em>If you undergo stem cell transplantation for your immune deficiency disorder, we  will consider you disabled until at least 12 months from the date of the  transplant.</p>
            <p id="114_00E3b">b. <em>Evaluation after the 12-month period has elapsed. </em>After the 12-month period has elapsed, we will consider any  residuals of your immune deficiency disorder as well as any residual  impairment(s) resulting from the treatment, such as complications arising from:</p>
            <p id="114_00E3bi">(i) Graft-versus-host (GVH) disease.</p>
            <p id="114_00E3bii">(ii) Immunosuppressant therapy, such as frequent infections.</p>
            <p id="114_00E3biii">(iii) Significant deterioration of other organ systems.</p>
            <p id="114_00E4">4. <em>Medication-induced immune suppression. </em>Medication effects can result in varying degrees of immune  suppression, but most resolve when the medication is ceased. However, if you  are prescribed medication for long-term immune suppression, such as after an  organ transplant, we will evaluate:</p>
            <p id="114_00E4a">a. The frequency and severity of infections.</p>
            <p id="114_00E4b">b. Residuals from the organ transplant itself, after the 12-month period has elapsed.</p>
            <p id="114_00E4c">c. Significant deterioration of other organ systems. </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00F">
                <strong>F. </strong><em>How do we document and evaluate HIV infection?</em>
                Any child with HIV infection, including one with a diagnosis of acquired immune deficiency syndrome (AIDS),
                may be found disabled under <a href="#114_11" title="Section 114.11">114.11</a> if his
                or her impairment meets the criteria in that listing or is medically equivalent to the criteria in that listing.
            </p>
            <p id="114_00F1">1. <em>Documentation of HIV infection.</em></p>
            <p id="114_00F1a">a. <em>Definitive documentation of HIV infection.</em> We may document a diagnosis of HIV infection by positive findings on one or more of the following definitive laboratory tests:</p>
            <p id="114_00F1ai">(i) HIV antibody screening test (for  example, enzyme immunoassay, or EIA), confirmed by a supplemental HIV antibody test such as the Western blot (immunoblot) or immunofluorescence assay, for any  child age 18 months or older.</p>
            <p id="114_00F1aii">(ii) HIV nucleic acid (DNA or RNA) detection test (for example, polymerase chain reaction, or PCR). </p>
            <p id="114_00F1aiii">(iii) HIV p24 antigen (p24Ag) test, for any child age 1 month or older.</p>
            <p id="114_00F1aiv">(iv) Isolation of HIV in viral culture. </p>
            <p id="114_00F1av">(v) Other tests that are highly specific for detection of HIV and that are consistent with the prevailing state  of medical knowledge.</p>
            <p id="114_00F1b">
                b. We will make every reasonable effort to obtain the results of your laboratory testing.
                Pursuant to § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0919f.htm" target="_blank" title="Code of Federal Regulations section 416.919f">416.919f</a>,
                we will purchase examinations or tests necessary to make a determination in your claim if no other acceptable documentation exists.
            </p>
            <p id="114_00F1c">c. <em>Other acceptable documentation of HIV infection.</em> We may also  document HIV infection without definitive laboratory evidence.</p>
            <p id="114_00F1ci">
                (i) We will accept a persuasive report from a physician that a positive diagnosis of your HIV infection was confirmed by an appropriate laboratory test(s),
                such as those described in <a href="#114_00F1a" title="Section 114.00 - Subsection F1a">114.00F1a</a>.
                To be persuasive, this report must state that you had the appropriate definitive laboratory test(s) for diagnosing your HIV infection and provide the results.
                The report must also be consistent with the remaining evidence of record.
            </p>
            <p id="114_00F1cii">(ii) We may also document HIV infection by the medical history, clinical and laboratory findings, and  diagnosis(es) indicated in the medical evidence, provided that such  documentation is consistent with the prevailing state of medical knowledge and  clinical practice and is consistent with the other evidence in your case  record. For example, we will accept a diagnosis of HIV infection without  definitive laboratory evidence of the HIV infection if you have an  opportunistic disease that is predictive of a defect in cell-mediated immunity  (for example, toxoplasmosis of the brain or Pneumocystis pneumonia (PCP)), and  there is no other known cause of diminished resistance to that disease (for  example, long-term steroid treatment or lymphoma). In such cases, we will make  every reasonable effort to obtain full details of the history, medical findings,  and results of testing.</p>
            <p id="114_00F2">2. <em>Documentation of the manifestations of HIV infection.</em></p>
            <p id="114_00F2a">a. <em>Definitive documentation of manifestations of HIV infection.</em> We may document manifestations of HIV infection by positive findings on definitive  laboratory tests, such as culture, microscopic examination of biopsied tissue  or other material (for example, bronchial washings), serologic tests, or on  other generally acceptable definitive tests consistent with the prevailing  state of medical knowledge and clinical practice. </p>
            <p id="114_00F2b">
                b. We will make every reasonable effort to obtain the results of your laboratory testing.&nbsp;
                Pursuant to § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0919f.htm" target="_blank" title="Code of Federal Regulations section 416.919f">416.919f</a>,
                we will purchase examinations or tests necessary to make a determination of your claim if no other acceptable documentation exists.
            </p>
            <p id="114_00F2c">c. <em>Other acceptable documentation of manifestations of HIV infection.</em> We may also document manifestations of HIV infection without definitive  laboratory evidence. </p>
            <p id="114_00F2ci">(i) We will accept a persuasive report from a physician that a positive diagnosis of your manifestation of HIV  infection was confirmed by an appropriate laboratory test(s). To be persuasive,  this report must state that you had the appropriate definitive laboratory  test(s) for diagnosing your manifestation of HIV infection and provide the  results. The report must also be consistent with the remaining evidence of  record.</p>
            <p id="114_00F2cii">
                (ii) We may also document manifestations of HIV infection without the definitive laboratory evidence described
                in 114.00F2a,
                provided that such documentation is consistent with the  prevailing state of medical knowledge and clinical practice and is consistent with the other evidence in your case record.
                For example, many conditions are now commonly diagnosed based on some or all of the following:
                Medical history, clinical manifestations, laboratory findings (including appropriate medically acceptable imaging), and treatment responses.
                In such cases, we will make every reasonable effort to obtain full details of the history, medical findings, and results of testing.
            </p>
            <p id="114_00F3">3. <em>Disorders associated with HIV infection 
                (<a href="#114_11A" title="Section 114.11 - Subsection A">114.11A</a>-<a href="#114_11E" title="Section 114.11 - Subsection E">E</a>). </em></p>
            <p id="114_00F3a">
                a. <em>Multicentric Castleman disease</em>
                (MCD, <a href="#114_11A" title="Section 114.11 - Subsection A">114.11A</a>)
                affects multiple groups of lymph nodes and organs containing lymphoid tissue.
                This widespread involvement distinguishes MCD from <em>localized</em> (or unicentric) Castleman disease, which affects only a single set of lymph nodes.
                While not a cancer, MCD is  known as a lymphoproliferative disorder.&nbsp;
                Its clinical presentation and progression is similar to that of lymphoma, and its treatment may include radiation or chemotherapy.
                We require characteristic findings on microscopic examination of the biopsied lymph nodes or other generally acceptable methods consistent
                with the prevailing state of medical knowledge and clinical practice to establish the diagnosis.
                Localized (or unicentric) Castleman disease does not meet or medically equal the criterion
                in <a href="#114_11A" title="Section 114.11 - Subsection A">114.11A</a>, 
                but we may evaluate it under the criteria in <a href="#114_11G" title="Section 114.11 - Subsection G">114.11G</a>
                or <a href="14.00-Immune-Adult.htm#14_11I" title="14.00 Immune System Disorders Page, Section 14.11 - Subsection I" target="_blank">14.11I</a> in part A.
            </p>
            <p id="114_00F3b">
                b. <em>Primary central nervous system lymphoma</em>
                (PCNSL, <a href="#114_11B" title="Section 114.11 - Subsection B">114.11B</a>) originates in the brain, spinal cord, meninges, or eye.
                Imaging tests (for example, MRI) of the brain, while not diagnostic, may show a single lesion or multiple lesions in the white matter of the brain.
                We require characteristic findings on  microscopic examination of the cerebral spinal fluid or of the biopsied brain tissue,
                or other generally acceptable methods consistent with the prevailing state of medical knowledge and clinical practice to establish the diagnosis.
            </p>
            <p id="114_00F3c">
                c. <em>Primary effusion lymphoma</em>
                (PEL, <a href="#114_11C" title="Section 114.11 - Subsection C">114.11C</a>) is also known as body cavity lymphoma.
                We require characteristic findings on microscopic examination of the effusion fluid or of the biopsied tissue from the affected internal organ,
                or other generally acceptable methods consistent with the prevailing  state of medical knowledge and clinical practice to establish the diagnosis.
            </p>
            <p id="114_00F3d">
                d. <em>Progressive multifocal leukoencephalopathy</em>
                (PML, <a href="#114_11D" title="Section 114.11 - Subsection D">114.11D</a>) is a progressive neurological degenerative syndrome caused by the John Cunningham (JC) virus in immunosuppressed children.
                Clinical findings of PML include clumsiness, progressive weakness, and visual and speech changes.
                Personality and cognitive changes may also occur. We require appropriate clinical findings, characteristic white matter lesions on MRI,
                and a positive PCR test for the JC virus in the cerebrospinal fluid to establish the diagnosis.
                We also accept a positive brain biopsy for JC virus or other generally acceptable methods consistent with the prevailing state of medical knowledge and clinical practice to establish the diagnosis.
            </p>
            <p id="114_00F3e">
                e. <em>Pulmonary Kaposi sarcoma</em>
                (Kaposi sarcoma in the lung, <a href="#114_11E" title="Section 114.11 - Subsection E">114.11E</a>)
                is the most serious form of Kaposi sarcoma (KS). Other internal KS tumors (for example, tumors of the gastrointestinal tract) have a more variable prognosis.
                We require characteristic findings on microscopic examination of the induced sputum, bronchoalveolar lavage washings,
                or of the biopsied transbronchial tissue,
                or other generally acceptable methods consistent with the prevailing state of medical knowledge and clinical practice to establish the diagnosis.
            </p>
            <p id="114_00F4">
                4. <em>CD4 measurement (<a href="#114_11F" title="Section 114.11 - Subsection F">114.11F</a>).</em>
                To evaluate your HIV infection under <a href="#114_11F" title="Section 114.11 - Subsection F">114.11F</a>, we require one measurement of your absolute CD4 count
                (also known as CD4 count or CD4+ T-helper lymphocyte count) or CD4 percentage for children from birth to attainment of age 5,
                or one measurement of your absolute CD4 count for children from age 5 to attainment of age 18.
                These measurements (absolute CD4 count or CD4 percentage)
                must occur within the period we are considering in connection with your application or continuing disability review.
                If you have more than one CD4 measurement within this period, we will use your lowest absolute CD4 count or your lowest CD4 percentage.
            </p>
            <p id="114_00F5">5. <em>Complications of HIV infection requiring hospitalization (<a href="#114_11G" title="Section 114.11 - Subsection G">114.11G</a>). </em></p>
            <p id="114_00F5a">a. Complications of HIV infection may include infections (common or opportunistic), cancers, and other conditions. Examples of complications that may result in hospitalization include:  Depression; diarrhea; immune reconstitution inflammatory syndrome; malnutrition;  and PCP and other severe infections.</p>
            <p id="114_00F5b">
                b. Under <a href="#114_11G" title="Section 114.11 - Subsection G">114.11G</a>,
                we require three hospitalizations within a 12-month period that are at least 30 days apart and that result from a complication(s) of HIV infection.
                The hospitalizations may be for the same complication or different complications of HIV infection and are not limited to the examples of complications that may result in hospitalization
                listed in <a href="#114_00F5a" title="Section 114.00 - Subsection F5a">114.00F5a</a>.
                All three hospitalizations must occur  within the period we are considering in connection with your application or continuing disability review.
                Each hospitalization must last at least 48 hours, including hours in a hospital emergency department immediately before the hospitalization.
            </p>
            <p id="114_00F5c">
                c. We will use the rules on medical equivalence
                in § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a>
                to evaluate your HIV infection if you have fewer, but longer, hospitalizations, or more frequent, but shorter, hospitalizations,
                or if you receive nursing, rehabilitation, or other care in alternative settings.
            </p>
            <p id="114_00F6">
                6. <em>Neurological manifestations specific to children (<a href="#114_11H" title="Section 114.11 - Subsection H">114.11H</a>).</em>
                The methods of identifying and evaluating neurological manifestations may vary depending on a child's age. For example, in an infant,
                impaired brain growth can be documented by a decrease in the growth rate of the head. In an older child,
                impaired brain growth may be documented by brain atrophy on a CT scan or MRI.
                Neurological manifestations may present in the loss of acquired developmental milestones
                (developmental regression) in infants and young children or, in the loss of acquired intellectual abilities in school-age children and adolescents.
                A child may demonstrate loss of intellectual abilities by a decrease in IQ scores, by forgetting information previously learned,
                by inability to learn new information, or by a sudden onset of a new learning disability.
                When infants and young children present with serious developmental delays (without regression),
                we evaluate the child's impairment(s) under <a href="112.00-MentalDisorders-Childhood.htm#112_00" target="_blank" title="112.00 Mental Disorders - Childhood Page, Section 112.00">112.00</a>.
            </p>
            <p id="114_00F7">7. <em>Growth failure due to HIV immune suppression (<a href="#114_11I" title="Section 114.11 - Subsection I">114.11I</a>).</em>&nbsp; </p>
            <p id="114_00F7a">
               a. To evaluate growth failure due to  HIV immune suppression,
                we require documentation of the laboratory values described in <a href="#114_11I1" title="Section 114.11 - Subsection I1">114.11I1</a>
                and the growth measurements in <a href="#114_11I2" title="Section 114.11 - Subsection I2">114.11I2</a> or <a href="#114_11I3" title="Section 114.11 - Subsection I3">114.11I3</a>
                within the same consecutive 12-month period.
                The dates of laboratory findings may be different from the dates of growth measurements.
            </p>
            <p id="114_00F7b">
                b. Under <a href="#114_11I2" title="Section 114.11 - Subsection I2">114.11I2</a> and <a href="#114_11I3" title="Section 114.11 - Subsection I3">114.11I3</a>,
                we use the appropriate table under <a href="105.00-Digestive-Childhood.htm#105_08B" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.08 - Subsection B">105.08B</a>
                in the digestive system to determine whether a child’s growth is less than the third percentile.
            </p>
            <p id="114_00F7bi">(i) For children from birth to  attainment of age 2, we use the weight-for-length table corresponding to the  child’s gender (Table I or Table II). </p>
            <p id="114_00F7bii">(ii) For children from age 2 to  attainment of age 18, we use the body mass index (BMI)-for-age corresponding to  the child’s gender (Table III or Table IV). </p>
            <p id="114_00F7biii">
                (iii) BMI is the ratio of a child’s  weight to the square of his or her height.
                We calculate BMI using the formulas in the digestive disorders body system (<a href="105.00-Digestive-Childhood.htm#105_00" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.00">105.00</a>).
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00G"><strong>G. </strong><em>How do we consider the  effects of treatment in evaluating your autoimmune disorder, immune deficiency  disorder, or HIV infection?</em><strong> </strong></p>
            <p id="114_00G1">1. <em>General. </em>If your impairment does not  otherwise meet the requirements of a listing, we will consider your medical  treatment in terms of its effectiveness in improving the signs, symptoms, and  laboratory abnormalities of your specific immune system disorder or its  manifestations, and in terms of any side effects that limit your functioning.  We will make every reasonable effort to obtain a specific description of the  treatment you receive (including surgery) for your immune system disorder. We  consider:</p>
            <p id="114_00G1a">a. The effects of medications you take.</p>
            <p id="114_00G1b">b. Adverse side effects (acute and chronic).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00G1c">c. The intrusiveness and complexity of your treatment (for example, the dosing  schedule, need for injections).</p>
            <p id="114_00G1d">d. The effect of treatment on your mental functioning (for example, cognitive  changes, mood disturbance). </p>
            <p id="114_00G1e">e. Variability of your response to treatment (see <a href="#114_00G2" title="Section 114.00 - Subsection G2">114.00G2</a>). </p>
            <p id="114_00G1f">f. The interactive and cumulative effects of your treatments. For example, many  children with immune system disorders receive treatment both for their immune  system disorders and for the manifestations of the disorders or co-occurring  impairments, such as treatment for HIV infection and hepatitis C. The  interactive and cumulative effects of these treatments may be greater than the  effects of each treatment considered separately.</p>
            <p id="114_00G1g">g. The duration of your treatment. </p>
            <p id="114_00G1h">h. Any other aspects of treatment that may interfere with your ability to function.</p>
            <p id="114_00G2">2. <em>Variability of your response to treatment. </em>Your response to treatment and the adverse or beneficial consequences of your treatment may vary widely. The effects of your treatment  may be temporary or long term. For example, some children may show an initial  positive response to a drug or combination of drugs followed by a decrease in  effectiveness. When we evaluate your response to treatment and how your  treatment may affect you, we consider such factors as disease activity before  treatment, requirements for changes in therapeutic regimens, the time required  for therapeutic effectiveness of a particular drug or drugs, the limited number  of drug combinations that may be available for your impairment(s), and the  time-limited efficacy of some drugs. For example, a child with HIV infection or  another immune deficiency disorder who develops otitis media may not respond to  the same antibiotic regimen used in treating children without HIV infection or  another immune deficiency disorder, or may not respond to an antibiotic that he  or she responded to before. Therefore, we must consider the effects of your  treatment on an individual basis, including the effects of your treatment on  your ability to function.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00G3">
                3. <em>How we evaluate the effects of treatment for autoimmune disorders on your ability to function.</em>
                Some medications may have acute or long-term side effects. When we consider the effects of corticosteroids or other treatments for autoimmune disorders on your ability to  function,
                we consider the factors in <a href="#114_00G1" title="Section 114.00 - Subsection G1">114.00G1</a> and <a href="#114_00G2" title="Section 114.00 - Subsection G2">114.00G2</a>.
                Long-term corticosteroid treatment can cause ischemic necrosis of bone, posterior subcapsular cataract, impaired growth, weight gain, glucose intolerance,
                increased susceptibility to infection, and osteopenia that may result in a loss of function. In addition,
                medications used in the treatment of autoimmune disorders may also have effects on mental functioning, including cognition
                (for example, memory), concentration, and mood.
            </p>
            <p id="114_00G4">
                4. <em>How we evaluate the effects of treatment for immune deficiency disorders, excluding HIV infection, on your ability to  function. </em>
                When we consider the effects of your treatment for your immune deficiency disorder on your ability to function,
                we consider the factors in <a href="#114_00G1" title="Section 114.00 - Subsection G1">114.00G1</a> and <a href="#114_00G2" title="Section 114.00 - Subsection G2">114.00G2</a>.
                A frequent need for treatment such as intravenous immunoglobulin and gamma interferon therapy can be intrusive and interfere with  your ability to function.
                We will also consider whether you have chronic side effects from these or other medications, including severe fatigue, fever,
                headaches, high blood pressure, joint swelling, muscle aches, nausea, shortness of breath,
                or limitations in mental function including cognition (for example, memory) concentration, and mood.
            </p>
            <p id="114_00G5">5. <em>How we evaluate the effects of treatment for HIV infection on your ability to function.</em> </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00G5a">
                a. <em>General. </em>
                When we consider the effects of antiretroviral drugs (including the effects of highly active antiretroviral  therapy (HAART))
                and the effects of treatments for the manifestations of HIV infection on your ability to function,
                we consider the factors in <a href="#114_00G1" title="Section 114.00 - Subsection G1">114.00G1</a> and <a href="#114_00G2" title="Section 114.00 - Subsection G2">114.00G2</a>.
                Side effects of antiretroviral drugs include, but are not limited to: Bone marrow suppression, pancreatitis,
                gastrointestinal intolerance (nausea,  vomiting, diarrhea), neuropathy, rash, hepatotoxicity, lipodystrophy
                (fat redistribution, such as “buffalo hump”), glucose intolerance, and lactic acidosis. In addition,
                medications used in the treatment of HIV infection may also have effects on mental functioning, including cognition (for example,  memory),
                concentration, and mood, and may result in malaise, severe fatigue, joint and muscle pain, and insomnia.
                The symptoms of HIV infection and the side effects of medication may be indistinguishable from each other.
                We will consider all of your functional limitations, whether they result from your symptoms or signs of HIV infection or the side effects of your treatment.
            </p>
            <p id="114_00G5b">b. <em>Structured treatment interruptions. </em>A  structured treatment interruption (STI, also called a “drug holiday”) is a  treatment practice during which your treating source advises you to stop taking  your medications temporarily. An STI in itself does not imply that your medical  condition has improved; nor does it imply that you are noncompliant with your  treatment because you are following your treating source’s advice. Therefore,  if you have stopped taking medication because your treating source prescribed  or recommended an STI, we will not find that you are failing to follow  treatment or draw inferences about the severity of your impairment on this fact  alone. We will consider why your treating source has prescribed or recommended  an STI and all the other information in your case record when we determine the  severity of your impairment.</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00G6">6. <em>When there is  no record of ongoing treatment. </em>If you have not received ongoing treatment  or have not had an ongoing relationship with the medical community despite the  existence of a severe impairment(s), we will evaluate the medical severity and  duration of your immune system disorder on the basis of the current objective  medical evidence and other evidence in your case record, taking into  consideration your medical history, symptoms, clinical and laboratory findings,  and medical source opinions. If you have just begun treatment and we cannot  determine whether you are disabled based on the evidence we have, we may need  to wait to determine the effect of the treatment on your ability to develop and  function in an age‑appropriate manner. The amount of time we need to wait will  depend on the facts of your case. If you have not received treatment, you may  not be able to show an impairment that meets the criteria of one of the immune  system disorders listings, but your immune system disorder may medically equal  a listing or functionally equal the listings.</p>
            <p id="114_00H">
                <strong>H. </strong><em>How do we consider your symptoms, including your pain, severe fatigue, and malaise? </em>
                Your symptoms, including pain, severe fatigue, and malaise,
                may be important factors in our determination whether your immune system disorder(s) meets or medically equals a listing or in our determination whether you otherwise have marked
                and severe functional limitations. In order for us to consider your symptoms,
                you must have medical signs or laboratory findings showing the existence of a medically determinable impairment(s) that could reasonably be expected to produce the symptoms.
                If you have such an impairment(s), we will evaluate the intensity, persistence,
                and functional effects of your symptoms using the rules throughout <a href="#114_00" title="Section 114.00">114.00</a> and in our other regulations.
                See §§ <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0921.htm" target="_blank" title="Code of Federal Regulations section 416.921">416.921</a>
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0929.htm" target="_blank" title="Code of Federal Regulations section 416.929">416.929</a>.
                Additionally, when we assess the credibility of your complaints about your symptoms and their functional effects,
                we will not draw any inferences from the fact that you do not receive treatment or that you are not following treatment without considering all of the relevant evidence in your case record,
                including any explanations you provide that may explain why you are not receiving or following treatment.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00I"><strong>I.</strong> <em>How do we consider the impact of your immune system disorder on your  functioning?</em></p>
            <p id="114_00I1">
                1. We will consider all relevant information in your case record to determine the full impact of your immune system disorder,
                including HIV infection, on your ability to function. Functional limitation may result from the impact of the disease process itself on your mental functioning,
                physical functioning, or both your mental and physical functioning. This could result from persistent or intermittent symptoms, such as depression, diarrhea,
                severe fatigue, or pain, resulting in a limitation of your ability to acquire information, to concentrate, to persevere at a task, to interact with others,
                to move about, or to cope with stress. You may also have limitations because of your treatment and its side effects
                (see <a href="#114_00G" title="Section 114.00 - Subsection G">114.00G</a>).
            </p>
            <p id="114_00I2">
                2. Important factors we will consider when we evaluate your functioning include, but are not limited to:
                Your symptoms (see <a href="#114_00H" title="Section 114.00 - Subsection H">114.00H</a>),
                the frequency and duration of manifestations of your immune system disorder, periods of exacerbation and remission, and the functional impact of your treatment,
                including the side effects of your medication (see <a href="#114_00G" title="Section 114.00 - Subsection G">114.00G</a>).
                See §§ <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0924a.htm" target="_blank" title="Code of Federal Regulations section 416.924a">416.924a</a>
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926a.htm" target="_blank" title="Code of Federal Regulations section 416.926a">416.926a</a>
                for additional guidance on the factors we consider when we evaluate your functioning.
            </p>
            <p id="114_00I3">
                3. We will use the rules in
                §§ <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0924a.htm" target="_blank" title="Code of Federal Regulations section 416.924a">416.924a</a>
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926a.htm" target="_blank" title="Code of Federal Regulations section 416.926a">416.926a</a>
                to evaluate your functional limitations and determine  whether your impairment functionally equals the listings.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00J"><strong>J. </strong><em>How do we  evaluate your immune system disorder when it does not meet one of the  listings?<strong></strong></em></p>
            <p id="114_00J1">1. These listings are only examples of immune system  disorders that we consider severe enough to result in marked and severe  functional limitations. If your impairment(s) does not meet the criteria of any  of these listings, we must also consider whether you have an impairment(s) that  satisfies the criteria of a listing in another body system.</p>
            <p id="114_00J2">2. Individuals with immune system disorders, including HIV infection, may  manifest signs or symptoms of a mental impairment or of another physical impairment. For example, HIV infection may accelerate the  onset of conditions such as diabetes or affect the course of or treatment  options for diseases such as cardiovascular disease or hepatitis. We may evaluate these impairments under the affected body system. For example,  we will evaluate:</p>
            <p id="114_00J2a">a. Growth impairment under <a href="100.00-GrowthImpairment-Childhood.htm#100_00" title="Low Birth Weight and Failure to Thrive - Childhood, Section 100.00" target="_blank">100.00</a>.</p>
            <p id="114_00J2b">
                b. Musculoskeletal involvement, such as surgical reconstruction of a joint,
                under <a href="101.00-Musculoskeletal-Childhood.htm#101_00" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00" target="_blank">101.00</a>.
            </p>
            <p id="114_00J2c">
                c. Ocular involvement, such as dry eye,
                under <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>.
            </p>
            <p id="114_00J2d">
                d. Respiratory impairments, such as pleuritis,
                under <a href="103.00-Respiratory-Childhood.htm#103_00" target="_blank" title="103.00 Respiratory Disorders - Childhood Page, Section 103.00">103.00</a>.
            </p>
            <p id="114_00J2e">
                e. Cardiovascular impairments, such as cardiomyopathy,
                under <a href="104.00-Cardiovascular-Childhood.htm#104_00" target="_blank" title="104.00 Cardiovascular System - Childhood Page, Section 104.00">104.00</a>.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_00J2f">
                f. Digestive impairments, such as hepatitis (including  hepatitis C) or weight loss as a result of HIV infection that affects the digestive system,
                under <a href="105.00-Digestive-Childhood.htm#105_00" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.00">105.00</a>.
            </p>
            <p id="114_00J2g">
                g. Genitourinary impairments, such as nephropathy,
                under <a href="106.00-Genitourinary-Childhood.htm#106_00" target="_blank" title="106.00 Genitourinary Disorders - Childhood Page, Section 106.00">106.00</a>.
            </p>
            <p id="114_00J2h">
                h. Hematologic abnormalities, such as anemia, granulocytopenia, and thrombocytopenia,
                under <a href="107.00-HematologicalDisorders-Childhood.htm#107_00" target="_blank" title="107.00 Hematological Disorders - Childhood Page, Section 107.00">107.00</a>.
            </p>
            <p id="114_00J2i">
                i. Skin impairments, such as persistent fungal and  other infectious skin eruptions, and photosensitivity,
                under <a href="108.00-Skin-Childhood.htm#108_00" target="_blank" title="108.00 Skin Disorders - Childhood Page, Section 108.00">108.00</a>.
            </p>
            <p id="114_00J2j">
                j. Neurologic impairments, such as neuropathy or  seizures,
                under <a href="111.00-Neurological-Childhood.htm#111_00" title="111.00 Neurological - Childhood Page, Section 111.00" target="_blank">111.00</a>.
            </p>
            <p id="114_00J2k">
                k. Mental disorders, such as depression, anxiety, or cognitive deficits,
                under <a href="112.00-MentalDisorders-Childhood.htm#112_00" target="_blank" title="112.00 Mental Disorders - Childhood Page, Section 112.00">112.00</a>.
            </p>
            <p id="114_00J2l">
                l. Allergic disorders, such as asthma or atopic dermatitis,
                under <a href="103.00-Respiratory-Childhood.htm#103_00" target="_blank" title="103.00 Respiratory Disorders - Childhood Page, Section 103.00">103.00</a> 
                or <a href="108.00-Skin-Childhood.htm#108_00" target="_blank" title="108.00 Skin Disorders - Childhood Page, Section 108.00">108.00</a> or under the criteria in another affected body system.<u></u>
            </p>
            <p id="114_00J2m">
                m. Syphilis or neurosyphilis under the criteria for  the affected body system,
                for example, <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a> Special senses and speech,
                <a href="104.00-Cardiovascular-Childhood.htm#104_00" target="_blank" title="104.00 Cardiovascular System - Childhood Page, Section 104.00">104.00</a> Cardiovascular system,
                or <a href="111.00-Neurological-Childhood.htm#111_00" title="111.00 Neurological - Childhood Page, Section 111.00" target="_blank">111.00</a> Neurological.
            </p>
            <p id="114_00J3">
                3. If you have a severe medically determinable impairment(s) that does not meet a listing,
                we will determine whether your impairment(s) medically equals a listing.
                (See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a>.)
                If it does not, we  will also consider whether you have an impairment(s) that functionally equals the listings.
                (See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926a.htm" target="_blank" title="Code of Federal Regulations section 416.9266a">416.926a</a>.)
                We use the rules in § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994a.htm" target="_blank" title="Code of Federal Regulations section 416.994a">416.994a</a> when we decide whether you continue to be disabled.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_01"><strong>114.01&nbsp; <em>Category  of Impairments, Immune System Disorders</em></strong></p>
            <p id="114_02">
                <strong><em>114.02&nbsp; </em></strong><strong><em>Systemic lupus erythematosus</em></strong>,
                as described in <a href="#114_00D1" title="Section 114.00 - Subsection D1">114.00D1</a>.
                With involvement of two or more organs/body systems, and with:
            </p>
            <p id="114_02A"><strong>A. </strong>One of the  organs/body systems involved to at least a moderate level of severity;</p>
            <p>AND</p>
            <p id="114_02B"><strong>B. </strong>At least two of the  constitutional symptoms and signs (severe fatigue, fever, malaise, or  involuntary weight loss).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_03">
                <strong><em>114.03</em></strong>&nbsp;<strong><em>Systemic vasculitis</em></strong>,
                as described in <a href="#114_00D2" title="Section 114.00 - Subsection D2">114.00D2</a>.
                With involvement of two or more organs/body systems, and with:
            </p>
            <p id="114_03A"><strong>A. </strong>One of the organs/body systems involved to at  least a moderate level of severity;</p>
            <p>AND</p>
            <p id="114_03B"><strong>B.</strong> At least two of the constitutional symptoms  and signs (severe fatigue, fever, malaise, or involuntary weight loss).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_04">
                <strong><em>114.04</em></strong>&nbsp; <strong><em>Systemic sclerosis (scleroderma).</em></strong>
                As described in <a href="#114_00D3" title="Section 114.00 - Subsection D3">114.00D3</a>. With:
            </p>
            <p id="114_04A"><strong>A.</strong> Involvement of two or more organs/body systems, with:</p>
            <p id="114_04A1">1. One of the organs/body systems  involved to at least a moderate level of severity; and</p>
            <p id="114_04A2">2. At least two of the constitutional  symptoms and signs (severe fatigue, fever, malaise, or involuntary weight  loss).</p>
            <p>OR</p>
            <p id="114_04B"><strong>B.</strong> One of the following:</p>
            <p id="114_04B1">
                1. Toe contractures or fixed deformity of one or both feet,
                <!--resulting in the inability to ambulate effectively as defined in <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>; or--> and medical documentation of at least <em>one</em> of the following:<br>
				</p><ol type="a">
  					<li>
						A documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a walker, bilateral canes, or bilateral crutches (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) or a wheeled and seated mobility device involving the use of both hands (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6ei" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(i)" target="_blank">101.00C6e(i)</a>); or
					</li>
  					<li>
						An inability to use one upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>), and a documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a one-handed, 
						hand-held assistive device (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) that requires the use of the other upper extremity or a wheeled and seated mobility device involving the use of one hand (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6eii" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(ii)" target="_blank">101.00C6e(ii)</a>); or
					</li>
				</ol>
            <p></p>
            <p id="114_04B2">
                2. Finger contractures or fixed  deformity in both hands<!--,
                resulting in the inability to perform fine and gross movements effectively as defined in--> and medical documentation of an inability to use <em>both</em> upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>); or
            </p>
            <p id="114_04B3">
                3. Atrophy with irreversible damage in one or both lower extremities<!--, resulting in the inability to ambulate effectively as defined in <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>; or--> and medical documentation of at least <em>one</em> of the following:<br>
				</p><ol type="a">
  					<li>
						A documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a walker, bilateral canes, or bilateral crutches (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) or a wheeled and seated mobility device involving the use of both hands (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6ei" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(i)" target="_blank">101.00C6e(i)</a>); or
					</li>
  					<li>
						An inability to use <em>one</em> upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>), and a documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a one-handed, hand-held assistive device (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) that requires the use of the other upper extremity or a wheeled and seated mobility device involving the use of one hand (see <a href="1.00-Musculoskeletal-Adult.htm#1_00C6eii" title="1.00 Musculoskeletal System Page, Section 1.00 - Subsection C6e(ii)" target="_blank">1.00C6e(ii)</a>); or
					</li>
				</ol>
            <p></p>
            <p id="114_04B4">
                4. Atrophy with irreversible damage in <em>both</em> upper extremities and medical documentation of an inability to use <em>both</em> upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>); or
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <!--<p>OR</p>-->
            <p id="114_04C"><strong>C.</strong> Raynaud’s  phenomenon, characterized by:</p>
            <p id="114_04C1">1. Gangrene involving at least two extremities; or</p>
            <p id="114_04C2">
                2. Ischemia with ulcerations of toes or fingers<!--,
                resulting in the inability to ambulate effectively or to perform fine and gross movements effectively as defined in <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a> and <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>--> and medical documentation of at least <em>one</em> of the following:<br>
				</p><ol type="a">
  					<li>
						A documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a walker, bilateral canes, or bilateral crutches (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) or a wheeled and seated mobility device involving the use of both hands (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6ei" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(i)" target="_blank">101.00C6e(i)</a>); or
					</li>
  					<li>
						An inability to use <em>one</em> upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>), and a documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a one-handed, hand-held assistive device (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) that requires the use of the other upper extremity or a wheeled and seated mobility device involving the use of one hand (see <a href="1.00-Musculoskeletal-Adult.htm#1_00C6eii" title="1.00 Musculoskeletal System Page, Section 1.00 - Subsection C6e(ii)" target="_blank">1.00C6e(ii)</a>); or
					</li>
  					<li>
						An inability to use <em>both</em> upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>).
					</li>
				</ol>
            <p></p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_05">
                <strong><em>114.05&nbsp; </em></strong><strong><em>Polymyositis and dermatomyositis.</em></strong>
                As described in <a href="#114_00D4" title="Section 114.00 - Subsection D4">114.00D4</a>. With:
            </p>
            <p id="114_05A">
                <strong>A.</strong> Proximal limb-girdle (pelvic or shoulder) muscle weakness<!--, resulting in inability to ambulate effectively or inability to perform fine and gross movements effectively as defined
                in <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a> and <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>--> and medical documentation of at least <em>one</em> of the following:<br>
				</p><ol type="1">
  					<li>
						A documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a walker, bilateral canes, or bilateral crutches (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) or a wheeled and seated mobility device involving the use of both hands (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6ei" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(i)" target="_blank">101.00C6e(i)</a>); or
					</li>
  					<li>
						An inability to use <em>one</em> upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>), and a documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a one-handed, hand-held assistive device (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) that requires the use of the other upper extremity or a wheeled and seated mobility device involving the use of one hand (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6eii" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(ii)" target="_blank">101.00C6e(ii)</a>); or
					</li>
  					<li>
						An inability to use <em>both</em> upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>); or
					</li>
				</ol>
            <p></p>
            <p>OR</p>
            <p id="114_05B"><strong>B.</strong> Impaired  swallowing (dysphagia) with aspiration due to muscle weakness.</p>
            <p>OR</p>
            <p id="114_05C"><strong>C.</strong> Impaired  respiration due to intercostal and diaphragmatic muscle weakness.</p>
            <p>OR</p>
            <p id="114_05D"><strong>D.</strong> Diffuse  calcinosis with limitation of joint mobility or intestinal motility.            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_06">
                <strong><em>114.06</em></strong>&nbsp;<strong><em>Undifferentiated and mixed connective tissue disease</em></strong>,
                as described in <a href="#114_00D5" title="Section 114.00 - Subsection D5">114.00D5</a>.
                With involvement of two or more organs/body systems, and with:
            </p>
            <p id="114_06A"><strong>A. </strong>One of the organs/body systems involved to at  least a moderate level of severity;</p>
            <p>AND</p>
            <p id="114_06B"><strong>B.</strong> At least two of the constitutional symptoms  and signs (severe fatigue, fever, malaise, or involuntary weight loss).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_07">
                <strong><em>114.07</em></strong>&nbsp; <strong><em>Immune deficiency disorders, excluding HIV  infection.</em></strong>
                As described in <a href="#114_00E" title="Section 114.00 - Subsection E">114.00E</a>. With:
            </p>
            <p id="114_07A"><strong>A.</strong> One or more of the following infections. The infection(s) must either be resistant to treatment or require hospitalization or intravenous treatment three or more times in a 12-month period.</p>
            <p id="114_07A1">1. Sepsis; or</p>
            <p id="114_07A2">2. Meningitis; or</p>
            <p id="114_07A3">3. Pneumonia; or</p>
            <p id="114_07A4">4. Septic arthritis; or</p>
            <p id="114_07A5">5. Endocarditis; or</p>
            <p id="114_07A6">6. Sinusitis documented by appropriate medically acceptable imaging.</p>
            <p>OR</p>
            <p id="114_07B">
                <strong>B.</strong> Stem cell transplantation as described under <a href="#114_00E3" title="Section 114.00 - Subsection E3">114.00E3</a>.
                Consider under a disability until at least 12 months from the date of transplantation. Thereafter, evaluate any residual impairment(s) under the criteria for the affected body system.
            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_08"><strong><em>114.08</em></strong>&nbsp; <strong><em>[Reserved]</em></strong></p>
            <p id="114_09">
                <strong><em>114.09</em></strong>&nbsp; <strong><em>Inflammatory arthritis</em>.</strong>
                As described in <a href="#114_00D6" title="Section 114.00 - Subsection D6">114.00D6</a>. With:
            </p>
            <p id="114_09A"><strong>A.</strong> Persistent inflammation or persistent  deformity of:</p>
            <p id="114_09A1">
                1. One or more major joints in a lower extremity (see <a href="#114_00C8" title="Section 114.00 - Subsection C8">114.00C8</a>) and medical documentation of at least <em>one</em> of the following:<br>
				</p><ol type="a">
  					<li>
						A documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a walker, bilateral canes, or bilateral crutches (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) or a wheeled and seated mobility device involving the use of both hands (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6ei" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(i)" target="_blank">101.00C6e(i)</a>); or
					</li>
  					<li>
						An inability to use <em>one</em> upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>), and a documented medical need (see <a href="#114_00C6" title="Section 114.00 - Subsection C6">114.00C6</a>) for a one-handed, hand-held assistive device (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6d" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6d" target="_blank">101.00C6d</a>) that requires the use of the other upper extremity or a wheeled and seated mobility device involving the use of one hand (see <a href="101.00-Musculoskeletal-Childhood.htm#101_00C6eii" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00 - Subsection C6e(ii)" target="_blank">101.00C6e(ii)</a>); or
					</li>
					
				</ol>
            <p></p>
            <p id="114_09A2">
                2. One or more major <!--peripheral--> joints in each upper extremity <!--resulting in the inability to perform fine or gross movements effectively
                (as defined in <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>).-->(see <a href="#114_00C8" title="Section 114.00 - Subsection C8">114.00C8</a>) and medical documentation of an inability to use <em>both</em> upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements (see <a href="#114_00C7" title="Section 114.00 - Subsection C7">114.00C7</a>); or
            </p>
            <!--<p>OR</p>-->
            <p id="114_09B"><strong>B.</strong> Inflammation or deformity in one or more major <!--peripheral--> joints of an upper or lower extremity (see <a href="#114_00C8" title="Section 114.00 - Subsection C8">114.00C8</a>) with:</p>
            <p id="114_09B1">1. Involvement of two or more  organs/body systems with one of the organs/body systems involved to at least a moderate level of severity; and</p>
            <p id="114_09B2">2. At least two of the constitutional symptoms or signs (severe fatigue, fever, malaise, or  involuntary weight loss).</p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p>OR</p>
            <p id="114_09C"><strong>C.</strong> Ankylosing spondylitis or other spondyloarthropathies, with:</p>
            <p id="114_09C1">1. Ankylosis (fixation) of the dorsolumbar or cervical spine as shown by appropriate medically acceptable imaging and measured on physical examination at 45° or more of flexion from the  vertical position (zero degrees); or</p>
            <p id="114_09C2">2. Ankylosis (fixation) of the dorsolumbar or cervical spine as shown by appropriate medically acceptable imaging and measured on physical examination at 30° or more of flexion (but  less than 45°) measured from the vertical  position (zero degrees), and involvement of two or more organs/body systems  with one of the organs/body systems involved to at least a moderate level of  severity.            </p>
            <p><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>
            <p id="114_10">
                <strong><em>114.10&nbsp;  Sjögren’s syndrome</em></strong>,
                as described in <a href="#114_00D7" title="Section 114.00 - Subsection D7">114.00D7</a>. With involvement of two or more organs/body systems, and with:
            </p>
            <p id="114_10A"><strong>A.</strong> One of the organs/body systems involved to at least a moderate level of severity;</p>
            <p>AND</p>
            <p id="114_10B"><strong>B.</strong> At least two of the constitutional symptoms and signs (severe fatigue, fever, malaise, or involuntary weight loss).</p>
            <p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b> </p>
            <p id="114_11">
                <strong><em></em>114.11 <em>Human immunodeficiency virus (HIV) infection.</em></strong>
                With documentation as described in <a href="#114_00F1" title="Section 114.00 - Subsection F1">114.00F1</a> and one of the following:
            </p>
            <p id="114_11A"><strong>A.</strong> Multicentric (not localized or unicentric) Castleman disease affecting multiple groups of lymph nodes or  organs containing lymphoid tissue (see 114.00F3a).</p>
            <p>OR</p>
            <p id="114_11B">
                <strong>B.</strong> Primary central nervous system lymphoma
                (see <a href="#114_00F3b" title="Section 114.00 - Subsection F3b">114.00F3b</a>).
            </p>
            <p>OR</p>
            <p id="114_11C">
                <strong>C.</strong> Primary effusion lymphoma
                (see <a href="#114_00F3c" title="Section 114.00 - Subsection F3c">114.00F3c</a>).
            </p>
            <p>OR</p>
            <p id="114_11D">
                <strong>D.</strong> Progressive multifocal leukoencephalopathy
                (see <a href="#114_00F3d" title="Section 114.00 - Subsection F3d">114.00F3d</a>).
            </p>
            <p>OR</p>
            <p id="114_11E">
                <strong>E.</strong> Pulmonary Kaposi sarcoma
                (see <a href="#114_00F3e" title="Section 114.00 - Subsection F3e">114.00F3e</a>).
            </p>
            <p>OR</p>
            <p id="114_11F">
                <strong>F.</strong> Absolute CD4 count or CD4 percentage
                (see <a href="#114_00F4" title="Section 114.00 - Subsection F4">114.00F4</a>):
            </p>
            <p id="114_11F1">1. For children from birth to attainment of age 1, absolute CD4 count of 500 cells/mm3 or less, or  CD4 percentage of less than 15 percent; or</p>
            <p id="114_11F2">2. For children from age 1 to attainment of age 5, absolute CD4 count of 200 cells/mm3 or less, or  CD4 percentage of less than 15 percent; or</p>
            <p id="114_11F3">3. For children from age 5 to attainment of age 18, absolute CD4 count of 50 cells/mm3 or less.</p>
            <p>OR</p>
            <p id="114_11G">
                <strong>G.</strong> Complication(s) of HIV infection requiring at least three hospitalizations within a 12-month period and at least 30 days apart
                (see <a href="#114_00F5" title="Section 114.00 - Subsection F5">114.00F5</a>). Each hospitalization must last at least 48 hours, including hours in a hospital emergency department immediately before the hospitalization.
            </p>
            <p>OR</p>
            <p id="114_11H">
                <strong>H.</strong> A neurological manifestation of HIV  infection (for example, HIV encephalopathy or peripheral neuropathy)
                (see <a href="#114_00F6" title="Section 114.00 - Subsection F6">114.00F6</a>) resulting in one of the following:
            </p>
            <p id="114_11H1">1. Loss of previously acquired  developmental milestones or intellectual ability (including the sudden onset of  a new learning disability), documented on two examinations at least 60 days  apart; or</p>
            <p id="114_11H2">2. Progressive motor dysfunction  affecting gait and station or fine and gross motor skills, documented on two  examinations at least 60 days apart; or</p>
            <p id="114_11H3">3. Microcephaly with head circumference  that is less than the third percentile for age, documented on two examinations  at least 60 days apart; or</p>
            <p id="114_11H4">4. Brain atrophy, documented by appropriate medically acceptable imaging.</p>
            <p>OR</p>
            <p id="114_11I">
                <strong>I.</strong> Immune suppression and growth failure
                (see <a href="#114_00F7" title="Section 114.00 - Subsection F7">114.00F7</a>) documented by 1 and 2, or by 1 and 3:&nbsp;
            </p>
            <p id="114_11I1">1. CD4 measurement: </p>
            <p id="114_11I1a">a. For children from birth to attainment of age 5, CD4 percentage of less than 20 percent; or </p>
            <p id="114_11I1b">b. For children from age 5 to attainment of age 18, absolute CD4 count of less than 200 cells/mm3  or CD4 percentage of less than 14 percent; and </p>
            <p id="114_11I2">2. For children from birth to attainment of age 2, three weight-for-length measurements that are: </p>
            <p id="114_11I2a">a. Within a consecutive 12-month  period; and </p>
            <p id="114_11I2b">b. At least 60 days apart; and </p>
            <p id="114_11I2c">
                c. Less than the third percentile on the appropriate weight-for-length table
                under <a href="105.00-Digestive-Childhood.htm#105_08B1" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.08 - Subsection B1">105.08B1</a>; or
            </p>
            <p id="114_11I3">3. For children from age 2 to attainment of age 18, three BMI-for-age measurements that are: </p>
            <p id="114_11I3a">a. Within a consecutive 12-month  period; and </p>
            <p id="114_11I3b">b. At least 60 days apart; and </p>
            <p id="114_11I3c">
                c. Less than the third percentile on  the appropriate BMI-for-age table
                under <a href="105.00-Digestive-Childhood.htm#105_08B2" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.08 - Subsection B2">105.08B2</a>.
            </p>
<p align="left"><b><a href="#Top"><span class="seventypercent">Back to Top</span></a></b></p>

 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt on" href="#" title="Back to Top"></a>


</body></html>